Cambium Bio Ltd
Research Cambium Bio Ltd (CMB) on Bullrun: market cap AUD 12.07M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCMB
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 12.07M
- Financial periodFY2025
- Net income-AUD 3.84M
- Free cash flow-AUD 5.25M
Valuation Snapshot
latest market cap is AUD 12.07M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 3.84M | -AUD 5.25M | n/a | -0.21 | AUD 166.41K | AUD 482.71K | AUD 1.84M |
| FY2024 | AUD 719 | -AUD 2.26M | -AUD 155.86K | 100.0% | -0.54 | AUD 2.86M | AUD 468.32K | AUD 2.78M |
| FY2023 | n/a | -AUD 3.38M | -AUD 659.66K | n/a | -1.1 | AUD 302.79K | AUD 1.95M | -AUD 1.81M |
| FY2022 | n/a | -AUD 4.31M | -AUD 3.60M | n/a | -1.4 | AUD 95.12K | AUD 1.01M | AUD 1.07M |
| FY2021 | AUD 7.96M | n/a | n/a | 100.0% | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 12.07M | n/a | n/a | n/a |
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cambium Bio Ltd's market cap?
Cambium Bio Ltd's market capitalization is AUD 12.07M.
What does Cambium Bio Ltd do?
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.